Recruiting

Dupilumab & Cemiplimab

Sponsor:

Centre hospitalier de l'Université de Montréal (CHUM)

Code:

NCT06743581

Conditions

Non-Small Cell Lung Cancer

Immunotherapy

Neoadjuvant Therapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cemiplimab

Dupilumab

Study Details

Brief summary:

This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. Phase 1b focuses on safety and feasibility, using a 3+3 design to monitor dose-limiting toxicities (DLTs), while Phase 2a assesses the major pathological response (MPR) rate with a Simon's two-stage minimax design. Secondary endpoints include event-free survival, overall survival, and translational objectives such as deep immune monitoring from patient samples, with the trial expected to enroll 24 patients at CHUM over five years.

Conditions

Non-Small Cell Lung Cancer

Immunotherapy

Neoadjuvant Therapy

Study ID

NCT06743581

Start date

Aug 19, 2025

Status verified date

Mar, 2026

Completion date

Feb, 2030

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Histological confirmation of NSCLC is required before treatment (however, patients with a smoking history and radiographic findings suggestive of NSCLC may consent prior to biopsy to combine research and diagnostic procedures.
  • Age ≥ 18 years.
  • ECOG performance status 0-1
  • Determined to be a surgical candidate for tumor resection by a multidisciplinary team.
  • Women of childbearing potential and men must use approved contraception during the study and for 4 months post-treatment. Pregnancy or suspected pregnancy must be reported immediately.
  • Adequate organ and marrow function.
  • Pre-treatment biopsies are mandatory, and tumors must be T1b or larger (>1cm) and amenable to biopsy as determined by a multidisciplinary team.
  • Patients must consent to provide blood at designated study time points.
  • Patients must consent to core needle biopsies (at least 3 samples, as deemed safe by the performing surgeon/radiologist) prior to treatment initiation

Exclusion Criteria:

  • History of autoimmune disorders or use of immunomodulatory drugs (including dupilumab) within 2 months prior to treatment initiation.
  • Active autoimmune disease requiring systemic treatment in the past year, excluding replacement therapies like thyroxine or insulin.
  • Use of immunosuppressive drugs or systemic steroids within 7 days prior to treatment, except chronic steroids ≤10mg prednisone or equivalent.
  • No smoking history or confirmed tissue or ctDNA evidence of actionable driver alterations (e.g. EGFR mutation, ALK, or ROS1 rearrangements)
  • Prior chemotherapy or radiotherapy for another primary tumor, or prior locoregional therapy to the target lesion. Therapy for a different cancer is acceptable.
  • Metastatic disease where surgery would not have curative intent.
  • Uncontrolled illness, including active infections requiring antibiotics, symptomatic heart failure, unstable angina, or psychiatric/social conditions impeding study compliance.
  • Pregnancy or nursing, due to potential harm to the fetus or infant.
  • Progressive malignancy requiring active treatment, except for certain stable cancers treated with curative intent
  • HIV infection with detectable viral load or not on a stable HAART regimen
  • Active Hepatitis B or C (PCR-detectable)
  • History of allogeneic hematopoietic or solid organ transplantation.
  • Documented hypersensitivity to protein therapeutics.
  • Any condition, therapy, or abnormality that may interfere with trial results, patient participation, or their best interest as per the investigator's judgment.

Study Design

Enrollment

24 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Neoadjuvant cemiplimab and dupilumab combination therapy

Neoadjuvant immunotherapy administered prior to thoracic surgery

Interventions

Cemiplimab

Cemiplimab 350 mg administered intravenously on day 1

Dupilumab

Dupilumab 600 mg administered subcutaneously on day 1

Primary outcome measure

  • Safety [ Time Frame: First 30 days after immunotherapy ]
  • Efficacy [ Time Frame: Day of surgery ]

Central Contacts and Locations

Central contacts

Antoine Desilets, MD, MSc

514-890-8444antoine.desilets.med@ssss.gouv.qc.ca

Wiam Belkaid, PhD

514-836-3273wiam.belkaid.chum@ssss.gouv.qc.ca

Locations

CHUM

Recruiting

Montreal, Quebec, Canada, H2X 0A9

Contacts

Anna Perez

5148908000anna.perez.chum@ssss.gouv.qc.ca

Principal Investigator:

Antoine Desilets, MD, MSc

More Information

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Last update posted

Aug 17, 2026

Last verified

Mar, 2026

Keywords

  • NSCLC
  • Neoadjuvant immunotherapy
  • Cemiplimab
  • Dupilumab

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM) on 2026-08-17.